Novartis

KYMRIAH

View Prices
  1. Home
    2.  / 
  2. Q Code
    3.  / KYMRIAH – Q2042

Manufacturer:

Novartis

Name:

KYMRIAH

HCPCS Code Descriptor:

Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Category:

Q Code

HCPCS:

Q2042

NDC(s):

00078-0846-19, 00078-0958-19

Primary Type:

Oncology

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

KYMRIAH is an Oncology drug manufactured by Novartis and administered via the Intravenous route of administration. The Q Code: Q2042 is aligned to the drug KYMRIAH.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

1/1/19

HCPCS Effective Date:

1/1/19

HCPCS Short Description:

Tisagenlecleucel car-pos t

Billing and Coding Guide:

Not Found

Patient Assistance:

Not Found